A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor
(TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the
F508del mutation (F/F)